All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Priority Review to Perioperative Durvalumab in Resectable Gastric/GEJ Cancer

July 28th 2025

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

Perioperative Tislelizumab Receives Positive CHMP Opinion for High-Risk Resectable NSCLC

July 28th 2025

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

IHC Testing May Bridge Gaps With NGS for Early Identification, Intervention in TP53-Mutant MDS and AML

July 28th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.

Lineage Plasticity and Treatment Resistance Highlight Need for Personalized mCRPC Strategies

July 28th 2025

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Immunotherapy Sequencing Must Be Personalized During Therapy Selection for Metastatic RCC

July 28th 2025

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC

July 27th 2025

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC

July 26th 2025

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC

July 26th 2025

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Personalizing Treatment for Atypical EGFR-Mutated NSCLC

July 25th 2025

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Understanding Underlying Resistance Mechanisms is Vital for Guiding Treatment Selection Post-Osimertinib in EGFR+ NSCLC

July 25th 2025

Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.

High-Risk Features Could Guide Treatment Intensification in First-Line EGFR-Mutated NSCLC

July 25th 2025

Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.

Isatuximab Plus VRd Approved in Europe for Transplant-Eligible Newly Diagnosed Multiple Myeloma

July 25th 2025

The European Commission has approved isatuximab plus VRd in transplant-eligible newly diagnosed multiple myeloma.

CHMP Recommends EU Approval of Vorasidenib for IDH1/2-Mutant Grade 2 Glioma

July 25th 2025

The CHMP has issued a positive opinion for the use of vorasidenib in IDH1/IDH2-mutant grade 2 glioma

Global Rise in Many Early-Onset GI Cancers Detailed in Two Dana-Farber Reviews, With Colorectal Cancer Leading the Trend

July 25th 2025

Fewer than 1 in 5 U.S. adults aged 45-49 screened for colorectal cancer, despite guidelines

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated Advanced Pancreatic Cancer

July 25th 2025

VS-7375 earned FDA fast track designation for KRAS G12D–mutant pancreatic ductal adenocarcinoma.

Sonrotoclax Plus Zanubrutinib Generates Durable Responses in R/R Mantle Cell Lymphoma

July 25th 2025

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

Cabozantinib Wins EU Approval for Previously Treated Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

July 24th 2025

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Ongoing Research Aims to Alter Management of HR+ Breast Cancer After Frontline CDK4/6 Inhibition

July 24th 2025

Laura Huppert, MD, outlines additional information needed to implement the SERENA-6 approach in hormone receptor–positive breast cancer.